



# Etiopathophysiological Functions of Carbohydrate-Lipid Interactions Associated with Obesity, Diabetes and Covid-19

**Chukwuma C\***

The Chrysanthus Centre for Future-Oriented Studies, Nigeria

**\*Corresponding author:** Dr. Chrysanthus Chukwuma Sr, Executive Director, The Chrysanthus Centre for Future-Oriented Studies, Abakaliki, Ebonyi State, Nigeria, Tel: +2348075011261; Email: Cfos\_nigeria@yahoo.com, chrysanthus\_chukwuma@yahoo.com

**Research Article**

**Volume 7 Issue 1**

**Received Date:** January 22, 2022

**Published Date:** February 28, 2022

**DOI:** 10.23880/doi-16000252

## Abstract

The extant COVID-19 pandemic has resulted in an expansive mortality due to the SARS-COV-2. The SARS-COV-2 is encompassed by a lipid bilayer that enhances fusion of the viral membrane to the host cell, replication, endocytosis, exocytosis and role of lipid metabolism in viral infectivity. In the absence of appropriate drugs and vaccines, there are never-ending opportunities for antiviral treatments. Consumption of diets suffused with carbohydrates and saturated fats contribute to obesity and diabetes prevalence, oxidative stress and comorbidities development as risk factors for COVID-19 pandemic as an emergency public health enigma. COVID-19 outbreak has invariably constituted a severe challenge to global public health system with resultant deficient approaches to stem the disorder but carbohydrates may provide accelerated diagnostics, appropriate, effective and efficient vaccines and therapeutic regimen. This paper provides a set of themes and modalities for analysing carbohydrate-lipid interactions as extrapolated to the issues and challenges of SARS-COV-2, the causative agent of the COVID-19 pandemic.

**Keywords:** Metabolism; Treatment; Diet; SARS-COV-2; Mortality; Vaccines

## Introduction

The current worldwide epidemic of obesity and type 2 diabetes has increased simultaneously with adverse metabolic events. There is expansive evidence that the type of carbohydrate consumed is important in the development or prevention of insulin resistance, obesity, and the metabolic syndrome. There is scarcity of published data on the combined effects of interactions between micronutrients, carbohydrates and lipids. However, there are extensive data supporting the benefits of the effects of both carbohydrates and lipids on various mechanisms of energy balance and diseases. Adequate measure is necessary to control carbohydrate-lipid interactions as they impact on obesity and diabetes. Investigation of the impact of foods and nutrients as complimentary strategies on COVID-19 treatment, recovery [1], restoration and sustainability [2]

are evident despite the intricate complexity of the disease, scarcity of veritable vaccines [3], emerging variants of concern [4], syndemics or comorbidities [5] geopolitics and gain-of-function research [6,7].

Associated factors in exacerbating obesity and diabetes

The current COVID-19 pandemic with its associated variants depict clinical findings with several risk factors for adverse morbidity, sequelae and mortality in susceptible and vulnerable persons presenting diverse risk factors, for instance, obesity and diabetes with resultant untoward trajectory of COVID-19 [8]. The presenting epidemic of obesity and type 2 diabetes globally has brought to the fore on the metabolic perturbations critical to aetiological events. Diet is a potent functionality in modulating metabolic syndrome expression that is associated with the levels and varieties of carbohydrates and fats as well as their

interactions as significant parameters [9]. Insulin resistance is significant in the metabolic syndrome due to relative insulin failure to govern the numerous biological effects on the metabolism of carbohydrates and lipids. There is paucity of published data on the combined impacts on interaction between the micronutrients, dietary fats and carbohydrate varieties. There are extant expansive data undergirding the advantageous impact of both fat and carbohydrates moieties on diverse mechanisms of energy balance metabolism and disorders. Certain mechanisms depict how the quality of dietary carbohydrate can affect weight gain by the absorption rate or the magnitude of carbohydrate fermentation.

Evidence abound indicating that the carbohydrate type is significant to developing or preventing insulin resistance, obesity, and the metabolic syndrome which need to be taken into cognizance to prevent, control and treat the presenting condition [10,11]. Diabetes constitute a metabolic disorder characterized by chronic hyperglycaemia and immune-mediated type 1 diabetes, insulin-resistant type 2 diabetes, gestational, genetic, environmental, infectious, behavioural or drug-induced impairments [12], and in syndemics or comorbidity relationship with obesity [13,14]. In the evolutionary process, the adaptation of living organisms has been associated with utilization of diverse nutrient sources, such as carbohydrates, lipids and proteins. However, carbohydrates and lipids constitute the two principal macromolecular components of intracellular storage compounds for energy production. Significantly, the anabolism and catabolism of these macromolecules are inextricably linked in organs concerned with nutrient regulation, such as the brain, liver, adipose tissue, pancreas and muscle [15]. The rate of obesity has been exacerbated globally, thus imposing on already augmented social burden regarding quality of life.

### Pathogenesis and Pathophysiological Issues

It has been difficult to define a clear trajectory for carbohydrate and lipid metabolism including their extant but elusive interactions. It has been determined that plants and animals conserve lipids from carbohydrates, but the reverse is evidenced in plants and, not practically imminent in animals [8]. In conventional human metabolism, carbohydrate-lipid interactions are not clearly evident, but the perturbations extant in diabetic metabolism manifest these interactions. Carbohydrate or lipid is utilizable as the major source of body fuel, however, the metabolic trajectory varies in chemical processes and functionalities. It is evident in the low content of body carbohydrate, such as in severe debilitating diabetes and starvation that lipids make provision for body fuel, and it is also exhibited in the blood and internal organs, particularly the hepatic organ

[12,16]. On recognition that there is abysmal decrease of carbohydrate necessary for metabolism, depot lipid is received by the hepatic organ and catabolized to ketone bodies, and peripherally burned in the muscles exclusive of carbohydrate metabolism [15]. This presents as a normal process, but inimical solely in diabetes. Diabetic obesity is frequently observed at the inception and immediately following insulin treatment. Ostensibly, hyperglycaemia induces this obesity that has been determined in unique presentations of lipaemia, diabetes and lipodystrophy. Lipaemia is obvious in two opposite metabolism phases: (i) anabolic is directed for storage; and (ii) catabolic in the storage flow to the hepatic organ for disease manifestation [16]. The evidence is inter alia fatty enlargement of the hepatic organ in diabetic children that may quickly disappear during control and treatment, even in chronic ketosis condition. As detected in high-income societies, an increase of obesity and metabolic syndrome prevalence predisposes to pathophysiological alterations which result in non-alcoholic fatty liver disorder that exacerbates acute hepatic organ derangement to concomitant cirrhosis and oncological hepatocellular degeneration [17]. Variations in insulin response, beta-oxidation, lipid transport and storage disruption, autophagy as well as established disequilibrium in chemokines and nuclear receptor signaling are implicated in these variations or alterations. Insulin, adipokines, epinephrine and other agonists stimulate pathways which regulate the activities of key enzymes of metabolism control in the integration of organismal carbohydrate and lipid metabolism. Defined overnutrition dysregulates these extant pathways with perturbative sequelae leading to insulin resistance and type 2 diabetes [17]. The pathogenesis of obesity, type 2 diabetes and insulin resistance is associated with perturbed lipid and carbohydrate metabolism. Obesity development is a complex process connected with genetic susceptibility and environmental factors that is not clearly elucidated [18]. Lipid aggregation in inflammation and ER stress is clinically evident in liver regeneration and hepatic oncological derangement [19]. The subclass of diabetes characterized as not insulin-responsive or dependent, NIDDM depicts insulin resistance and hyper-insulinaemia, with resultant glucose intolerance, hyperglycaemia and fulminant diabetes and comorbidity of ketosis and obesity [13]. In these perspectives, it is pellucid that obesity and dysfunctional metabolic disposition are defined risk factors for noncommunicable diseases, such as type 2 diabetes which may be compounded with coronavirus disease 2019 or COVID-19 [20].

### Genetic and Environmental Factors

Persons in advanced age, comorbidities and vulnerable populations are susceptible to COVID-19 as these factors

are inextricably-linked to genetic, epigenetic, environmental and interaction variables [21] in obesity and diabetes.. Obesity constitutes a significant aspect of metabolic syndrome, predisposing to type 2 diabetes development. There is exacerbation in the incidence of diabetes and metabolic syndrome with undefined aetiology for the increase in incidence. This may be influenced genetically in the prevalence of these disorders [22,23]. It has not been clearly determined how genetic variables have interactions with environmental and dietary aspects to accelerate their incidence [22,23]. It has been revealed that genes associated with pathways of carbohydrate, lipid and amino acid metabolism, as well as glycan biosynthesis, pathways in the metabolism of cofactors and vitamins, ubiquitin mediated proteolysis, pathways of signal transduction, interactions of neuroactive ligand-receptor, pathways of nervous system, and neurodegenerative perturbation pathways are upregulated in obesity in comparison to normal persons [24]. Obviously, genes associated with molecules of cell adhesion, cytokine-cytokine receptor interaction, insulin signaling and immune system pathways undergo down regulation in obesity. Genes implicated in signal transduction, actin cytoskeleton regulation, processing and presentation of antigen, complement and coagulation cascades, axon guidance and pathways of neurodegenerative disorders are upregulated in type 2 diabetic subjects with family history of diabetes in contradistinction to diabetic subjects devoid of any family history. Genes connected with pathways of oxidative phosphorylation, immune, nervous system and metabolic diseases are upregulated in diabetic subjects with diabetes family history, but not in diabetes devoid of any family history [24]. On the contrary, genes related in lipid and amino acid pathways, ubiquitin mediated proteolysis, signal transduction, insulin and PPAR signaling pathways are downregulated in individuals with diabetes and concomitant family history. It is evident that genes connected in inflammatory pathways are disparately expressed in both obesity and type 2 diabetes. These findings are indicative that genes associated with carbohydrate, lipid, and amino acid metabolic pathways, neuronal function and inflammation are significant in obesity and type 2 diabetes pathology. Genetic predisposition contributes immensely to obesity as determined by familial aggregation, twin and adoption studies [22,23]. Obesity results from energy intake, mainly accumulated as triglycerides surpassing energy expenditure [24]; and influenced by age, diet, developmental stage, genes and physical activity [25]. The prevalence increase of obesity correlates with type 2 diabetes prevalence, impaired glucose tolerance [26] and numerous complications of both disorders, such as arthritis, hypertension, sleep apnoea, cardiovascular disorders and organ perturbations [27]. As a result of the increase in obesity and diabetes prevalence, it is perspicuous that future life expectancy of affected subjects is likely to decline [28].

### Oxidation and Metabolism

The pathogenic SARS-COV-2 has the potential to enhance metabolic alterations during viral infection that promotes its survival, changes in cell morphology with concomitant inflammation and tissue damage, and alterations in glucose and lipid metabolism [29]. Competition for respiration among substrates in animal tissues is depicted in the quantitative interaction between glucose and fatty acids that is evident in the Glucose Fatty Acid Cycle of the reciprocal metabolic linkage between glucose and fatty acids. The production of glucose predisposes to glucose oxidation and glucose including lipid storage, with the inhibition of fatty acid oxidation. The availability of free fatty acids predisposes to fatty acid oxidation and oxidation, with inhibition of glucose oxidation and augmentation of glucose storage during depletion of glycogen reserves [30]. Evidence exists that fatty acid oxidation inhibits glucose production in liver with defined enzyme mechanisms. A permissive latitude for fatty acids during insulin secretory response of islet beta-cells is notable as a protective mechanism in continuous availability of respiratory substrate. Extended duration in islet beta-cell exposure to fatty acids debilitates the insulin secretory response to glucose and presenting mechanisms. Fatty acid oxidation is associated with impairment of glucose oxidation in uncontrolled type 1 and type 2 diabetes; with paucity of information in the role of fatty acids in the depletion of glucose storage or glycogen deposition. Type 2 diabetes depicts glucose storage inhibition resulting in protracted augmentation of plasma FFA I humans and experimental animals is connected with glycogen depletion; in contrast, glucose storage inhibition in type 2 diabetes is related to glycogen reduction [30]. The defined functionality of fatty acids in perturbed carbohydrate metabolism in type 2 diabetes paves way for future research.

Combustion pervades life, and ardent research directs itself on the prominent fuel substrates which provide sustenance, are in competition and interaction among themselves for respiratory combustion. Numerous features of imminent mutual interaction that is exhibited in both reciprocal and dependent characteristics between glucose and lipid metabolism have been elucidated [31]. These include (i) the inhibitory impacts of increased levels of fatty acids on glucose oxidation through inactivation of mitochondrial pyruvate dehydrogenase or by means of desensitization of insulin-mediated glucose transport; (ii) the inhibitory effects of augmented glucose content on fatty acid oxidation via malonyl-CoA regulation of fatty acid ingress into the mitochondria; and (iii) the stimulatory impacts of exacerbated glucose abundance on de novo lipogenesis, i.e. lipid synthesis from glucose by means of SREBP1c glycolytic and lipogenic enzyme regulation. It is posited that energy-dissipating substrate cycling linking

glucose and lipid metabolism to thermogenesis functions as a modulating mechanism that controls intramyocellular lipid homeostasis culminating in contributing to skeletal muscle protection against lipotoxicity [30-34].

Lipid oxidation rate may correlate with plasma free fatty acid contents. Lipid contribution to energy expenditure is greater in obese as compared to control subjects. This is usurped by lipids in the energy metabolism of both diabetic and non-diabetic obese individuals, and it is the resultant impact of their elevated fat contents. The concomitant decline in carbohydrate metabolism ostensibly results as sequelae to variations in glucose tolerance, with resultant retarded glucose storage and oxidation in the obese subject [35]. In normal pregnancy, it has been realized that plasma triglycerides are elevated 2-3 fold. Deficiency of a significant impact of diabetes, body weight, and augmented carbohydrate intake on blood lipids during gestation differentiates pregnancy from atherosclerosis-associated hypertriglyceridaemias and relates to a distinct physiologic regulatory mechanism [36].

Carbohydrate and lipid metabolism is markedly dependent on mitochondria regulated by NRF-1 [37]. The metabolic pathways are controlled via metabolic variations at levels of high energy substances, such as AMP/ATP and the NAD<sup>+</sup>/NADH ratios. Reduced levels of ATP activate AMPK that elicits the activation of eclectic transcription factors, NRF-1, that regulates both carbohydrate and lipid metabolism. Conversely, alterations in the NAD<sup>+</sup>/NADH ratios influence the activity of other metabolic regulators like the sirtuins which are protein deacetylases [37]. Sirtuins augment the activity of transcriptional co-activator, PGC-1 via deacetylation, the major co-activator of NRF-1. Further research is required to determine if sirtuins directly regulate NRF-1 activity in relation to carbohydrate and lipid metabolism.

COVID-19 infection as exemplified in varied infections induces an inflammatory response that is usually restricted to the respiratory system, but in fulminant episodes, an expansive proportion of the body is overwhelmed [38]. Thus, obesity has been associated with chronic oxidative stress, and dietary restriction and weight dissipation have resulted in remarkable decrease in oxidative stress indices within a short span of time [39].

### Diet, Control and Therapeutics

As exemplified above [38,39], dietary approaches and strategies are pertinent in diabetes and obesity management. Stringent dietary regulation with minimal carbohydrate diet has been extensively applied, that later subsided with novel applications of medications. The major objective has

been to ameliorate dietary fat intake in order to obviate the atherosclerotic disease risk, with less attention on carbohydrate quality and abundance. With exacerbating obesity and diabetes globally, the trend and target are on the diet micronutrient composition. Low carbohydrate diets have been effective in initial weight mitigation and glycaemic control improvement, with long-run acceptance and deteriorating lipid profile [40]. Modulations of extremely reduced carbohydrate contents involve restricting saturated fat and augmenting both carbohydrate and lipid. Decreasing saturated fat is ostensibly the key to reduce low-density lipoprotein, LDL cholesterol with retardation of adverse impacts of conventional very low carbohydrate diets. Augmented dietary protein predisposes satiety, decreased energy intake and concomitant improved glycaemic homeostasis, but devoid of substandard improvement in glycaemic regulation or cardiovascular sequelae regarding the impact of weight loss. Type 1 diabetes has responded to regulatory effects with low carbohydrate diets, without ketosis and hypoglycaemic complications. Carbohydrate-restricted diets exhibit effective weight reduction as low fat diets; and fat substitution for carbohydrate is invariably advantageous concerning cardiovascular disease risk without need for weight loss; and improves metabolic syndrome characteristics [41]. Low carbohydrate diets are dependent upon mechanisms of glucose directly or indirectly via insulin that is a major regulatory component in gluconeogenesis, glycogen metabolism, lipogenesis and lipolysis.

Studies have assessed the relative impact of fat compared to carbohydrate and the distinctiveness among fatty acids and variants of carbohydrates on insulin resistance and related risk factors for diabetes, cardiovascular disease and obesity. The fibre content of the carbohydrate diet ostensibly provides advantages regarding diabetic control, while lower cholesterol and postprandial blood glucose are connected with viscous fibres [42]. Resting energy expenditure and measurement of both carbohydrate and lipid oxidation rates as well as measurements observed in both fasting and parenterally fed states were determined [15]. Although, there were no variations in resting energy expenditure, a significant decrease  $p < 0.05$  in RQ 5% and carbohydrate oxidation rate, 24% accompanied by a concomitant exacerbation of lipid oxidation rate, 42% was detected in parenteral nutrition in fusion. There were no disparities in plasma insulin, glucose, and insulin resistance observed in pre- and post-infliximab [17]. Improvements in insulin resistance following anti-TNF- $\alpha$  therapy have been observed in inflammatory states in children, but no alterations were detected in adult patients presenting with Chron's disease [43].

There is growing evidence that dietary plant polyphenols are potential nutraceuticals and supplementary treatments for type 2 diabetes due to their biological attributes, such

as high concentration of phytochemicals and antioxidant capacity [44]. Findings from in vitro, animal models and human experiments indicated that plant-food polyphenols, and polyphenol-rich products (i) attenuate dyslipidaemia, hyperglycaemia and insulin resistance, (ii) potentiate adipose tissue metabolism, (iii) mitigate oxidative stress and stress-sensitive signaling pathways and inflammatory responses [45], as well as (iv) modulate carbohydrate and lipid metabolism. Polyphenols can contribute to the prevention and abatement of long-term diabetic sequelae, such as cardiovascular disorder, nephropathy, retinopathy and other predisposing factors [46,47]. At the molecular level, carbohydrates are intricately linked with immune components. Thus, carbohydrate-based systems potentially constitute features to combat COVID-19 [48]. In addition carbohydrates depict antifungal, antimicrobial and antiviral attributes which make them propitiously relevant to morphologically engage SARS-COV-2 in the provision of vaccines and therapeutic agents.

### Discussion

Diabetes constitute a metabolic disorder characterized by chronic hyperglycaemia and immune-mediated type 1 diabetes, insulin-resistant type 2 diabetes, gestational, genetic, environmental, infectious, behavioural or drug-induced impairments [12]. It is generally postulated that obesity and type 2 diabetes have escalated in prevalence globally with concomitant sequelae or complications in morbidity and mortality. The pathophysiology [49,50] or pathobiology of these conditions have been difficult to unravel or elucidate. Several hormone-like signaling agents which influence energy metabolism are emitted from adipocytes, such as leptin, as well as immature cells, such as tumour necrosis factor-alpha. Obesity and type 2 diabetes present marked gene-environment interaction [51]. Paucity of data is extant on the single-gene defects which result in these states, but in several instances, polygenic contributions have been detected [10,52]. The impact of the extant COVID-19 pandemic on present and future human growth and development perspicuously depends on inter alia the socioeconomic correlates with pertinence to ideologically behavioural imprint, macromolecular interactions, birth weight, obesity, diabetes, cardiovascular disorders and other communicable and noncommunicable diseases as also evident in SARS-COV-2 or COVID-19 perturbations [53-58].

### Conclusion

Numerous environmental states including fetal ambience, lifestyle and social diversions have been implicated in the predisposition of these ailments or disorders. Fundamentally, an imbalance between caloric ingress and energy dissipation elicits endocrine and/or metabolic responses exacerbating

the age-dependent dysregulation in lipid and carbohydrate metabolism in vulnerable populations and COVID-19 susceptible individuals.

### References

1. Cobre AF, Surek M, Vilhena RO, Boger B, Fachi MM, et al. (2021) Influence of foods and nutrients on COVID-19 recovery: A multivariate analysis of data from 170 countries using a generalized linear model. *Clin Nutr* S0261-5614(21): 00157-00166
2. Chukwuma Sr C (2021) Ecological analysis of the COVID-19 pandemic for restoration and sustainability. *Research and Advances in Pharmacy and Life Sciences* 3(1): 8-12.
3. Chukwuma Sr C (2021) Accessing vaccines with compliance to stem the emergence of the SARS-COV-2 or COVID-19 variants. 3<sup>rd</sup> (Vol.), 2<sup>nd</sup> (Edn.), eBook: *Research Trends of Microbiology*. MedDocs Publishers LLC, pp: 12-15.
4. Chukwuma Sr C (2021) Challenges and opportunities in accessing veritable vaccines and curbing the excesses of the SARS-COV-2 or COVID-19 variants. *Middle East Publishers Scholars International Journal of Biochemistry* 4(9): 108-111.
5. Chukwuma Sr C (2021) Syndemics of chronic and acute diseases in vulnerable populations.
6. Chukwuma Sr C (2021) Gain-of-Function Research and geopolitics in the emergence and reemergence of infectious diseases and microbiome variants. *International Journal of Chemical and Life Sciences* 10(8): 2197-2205.
7. Chukwuma Sr C (2022) Perspectives in the emergence and re-emergence of infectious diseases, geopolitics and gain-of-function research. *Middle East Publishers Scholars International Journal of Biochemistry* 5(1): 1-7.
8. Liu D, Zhang T, Wang Y and Xia L (2021) The centrality of obesity in the course of severe COVID-19. *Front Endocrinol (Lausanne)* 12: 620566.
9. Brown MA, Storlein LH, Huang X-F (2010) Dietary fat and carbohydrate composition: Metabolic diseases, Chapter 21. In: Montmayeur JP, le Coutre J, (Eds.), *Fat Detection, Task, Texture, and Post-ingestive Effects*. Boca Raton (FC): CRC Press/Taylor & Francis,
10. Chukwuma Sr C, Tuomilehto J (1998) The "thrifty" hypotheses: clinical and epidemiological significance for non-insulin-dependent diabetes mellitus and

- cardiovascular disease risk factors. *J Cardiovasc Risk* 5(1): 11-23.
11. Chukwuma Sr C (2019) Dynamic attributes of lipid and carbohydrate interactions in biosystems. *Recent trends in pharmaceutical sciences and research* 2(1): 45-53.
  12. Baynes HW (2015) Classification, pathophysiology, diagnosis and management of diabetes mellitus. *J Diabetes Metab* 6(5): 1000541.
  13. Candib LM (2007) Obesity and diabetes in vulnerable populations: reflection and proximal causes. *Ann Fam Med* 5(6): 547-556.
  14. Das UN, Rao AA (2007) Gene expression profile in obesity and type 2 diabetes mellitus. *Lipids in Health and Disease* 6: 35.
  15. Kim JB (2016) Dynamic cross talk, between metabolic organs in obesity and metabolic diseases. *Exp Mol Med* 48(3): e214.
  16. Lawrence RD (1941) Interactions of fat and carbohydrate metabolism – Aspects and therapies. *Proc R Soc Med* 35(1): 1-10.
  17. Hardie DG (2012) Organismal carbohydrate and lipid homeostasis. *Cold Spring Harbor Perspectives in Biology* 4(5): a006031.
  18. Musso G, Gambino R, Cassader M (2010) Obesity, diabetes and gut microbiota. The hygiene hypothesis expanded. *Diabetes Care* 33(10): 2277-2284.
  19. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, et al. (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. *J Hepatol* 56(4): 952-964.
  20. Stefan N, Birkenfeld AL, Schulze MB (2021) Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. *Nature Reviews Endocrinology* 17: 135-149.
  21. Alberti A, Schuelter-Trevisol F, Iser BPM, Traebert E, Freiberger V, et al. (2021) Obesity in people with diabetes in COVID-19 times: Important considerations and precautions to be taken. *World J Clin Cases* 9(20): 5358-5357.
  22. Stunkard AJ, Harris JR, Pedersen NL, McLearn GE (1990) The body mass index of twins who have been reared apart. *N Engl J Med* 322(21): 1483-1487.
  23. Bouchard C, Tremblay A (1997) Genetic influences on the response of body fat distribution to positive and negative energy balances in human identical twins. *J Nutr* 127(5): 943S-947S.
  24. Bray GA (2004) Medical consequences of obesity. *J Clin Endocrinol Metab* 89(6): 2583-2589.
  25. Kopelman PG (2004) Obesity as a medical problem. *Nature* 404: 635-643.
  26. Harris MI (1998) Diabetes in America: epidemiology and scope of the problem. *Diabetes Care* 21(3): C11-C14.
  27. Singla P, Bardoloi A, Parkash AA (2010) Metabolic effects of obesity: A review. *World J Diabetes* 1(3): 76-88.
  28. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, et al. (2005) A potential decline in life expectancy in the United States in the 21<sup>st</sup> century. *N Engl J Med* 352(11): 1138-1145.
  29. Silva MA, Alves da Silva ARP, Abrantes do Amaral M, Fragas MG, Canada NOS, et al. (2021) Metabolic alterations in SARS-COV-2 infection and its implication in kidney dysfunction. *Front Physiology* 12: 624698.
  30. Randle PJ (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. *Diab Metab Res Rev* 14(4): 263-283.
  31. Dulloo AG, Gubler M, Montani JP, Seydoux J, Solinas G, et al. (2004) Substrate cycling between de novo lipogenesis, and lipid oxidation: a thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity. *Proceedings of the Second Fribourg Obesity Research Conference (FORC-2003)*. *Int J Obes Relat Metab Disord* 28(4): S29-S37.
  32. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ (1993) Interaction between glucose and free fatty acid metabolism in human skeletal muscle. *J Clin Invest* 92(1): 91-98.
  33. Frayn KN (2003) The glucose-fatty acid cycle: a physiologic perspective. *Biochem Soc Trans* 31(6): 1115-1119.
  34. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA (1983) Effects of fatty acids on glucose production and utilization in man. *J Clin Invest* 72(5): 1737-1747.
  35. Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, et al. (1984) Study on lipid metabolism in obesity diabetes. *Metabolism* 33(2): 111-116.
  36. Warth MR, Knopp RH (1977) Metabolism in pregnancy: V. Interactions of Diabetes, Body Weight, Age, and High Carbohydrate Diet. *Diabetes* 26(11): 1056-1062.

37. Ferreira Z, Ayeleso A, Mukwevh OE (2014) Control of carbohydrate and lipid metabolism by NRF-1 and sirtuins: Implications on type 2 diabetes and obesity. *Chem Biol Lett* 1(2): 66-76.
38. Dandona P and Ghanim H (2021) Diabetes, obesity, COVID-19, and other anti diabetes drugs. *Diabetes Care* 44(9): 1929-1933.
39. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, et al. (2001) The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. *J Clin Endocrinol Metab* 86(1): 355-362.
40. Hall RM, Strong AP, Krebs JD (2016) Importance of low carbohydrate diets in diabetes management. *Nutr Diet Suppl* 8: 9-19.
41. Accurso A, Bernstein RK, Dahlqvist A, Draznin B, Feinman RD, et al. (2008) Dietary carbohydrate restriction in type 2 diabetes and metabolic syndrome: time for a critical appraisal. *Nutrition and Metabolism* 5: 9.
42. Hung T, Sievenpiper JL, Marchie A, Kendall CW, Jenkins DJ, et al. (2003) Fat versus carbohydrate in insulin resistance, obesity, diabetes and cardiovascular disease. *Curr Opin Clin Nutr Metab Care* 6(2): 165-176.
43. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC (2008) Carbohydrate and lipid metabolism following infliximab therapy in pediatric Chron's Disease. *Pediatric Research* 64(4): 673-676.
44. Bahadoran Z, Mirmiran P, Azizi F (2013) Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. *J Diab Metab Disorders* 12(1): 43.
45. Evans JL, Goldfine, ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocr Rev* 23(5): 599-622.
46. Pandey KB, Rizvi SI (2002) Plant polyphenols as dietary antioxidants in human health and disease. *Oxid Med Cell Longev* 2(5): 270-278.
47. Bahadoran Z, Golzarand M, Mirmiran P, Saadati N, Azizi F, et al. (2013) The association of dietary phytochemical index and cardiometabolic risk factors in adults: Tehran lipid and glucose study. *J Hum Nutr Diet* 26(1): 145-153.
48. Kumbhar SP, Pandya AK, Manjappa AS, Disouza JJ, Vandana B, et al. (2021) Carbohydrate-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19. *Carbohydrate Polymer Technologies and Applications* 2: 100052.
49. Chukwuma Sr C (2021) The complex interplay in the regulation of cardiac pathophysiological functionalities by protein kinases and phosphatases. *Jjournal of Cardiology & Cardiovascular Medicine. Journal of Cardiology and Cardiovascular Medicine* 6: 048-054.
50. Chukwuma Sr C (2021) Exploring the complex interplay in the regulation of cardiac pathophysiological functions by protein kinases and phosphatases. *International Journal of Biosciences and Biochemistry* 3(2): 1-7.
51. Chukwuma Sr C (2014) Is diabetes a model for gene-environment interaction in premature senescence? *JABH* 4(25): 84-93.
52. Romao I, Roth J (2008) Genetic and environmental interactions in obesity and type 2 diabetes. *J Am Dietetic Assoc* 108(4): S24-S28.
53. Chukwuma Sr C, Tuomilehto J (1998) The 'thrifty' hypotheses: Clinical and epidemiological significance for non-insulin-dependent diabetes mellitus and cardiovascular disease risk factors. *Journal of Cardiovascular Risk* 5(1): 11-23.
54. Bogin B, Varea C (2020) COVID-19, crisis, and emotional stress: A biocultural perspective of their impact on growth and development for the next generation. *Am J Him Biol* 32(5): e23474
55. Yaribeygi H, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) The impact of diabetes mellitus in COVID-19: A mechanistic review of molecular interactions. *Journal of Diabetes Research*.
56. Chukwuma Sr C (2019) Regulatory and metabolic interactions of carbohydrates and lipids in diabetes and obesity. *J Biotech Res* 5(11): 123-127.
57. Chukwuma Sr C (2018) Convergence on the constraints and challenges in the awareness, prevention, treatment and control of type 2 diabetes and related conditions. *Global Journal of Medical Research, GJMR* 17(3).
58. Chukwuma Sr C (2020) The complexity of communicable and noncommunicable diseases in vulnerable populations. *ABBSR* 3(1).

